Bradykinin B2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings: Mediation by autocrine/paracrine mechanisms

Circulation Research

Volumn 81, Issue 5, 1997, Pages 774-784

  Seyedi, Nahid ^a   Win, Terrance ^a   Lander, Harry M ^a   Levi, Roberto ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adrenergic nerve ending; Autocrine paracrine; Bradykinin; Cardiac synaptosome; Norepinephrine exocytosis

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 9 METHYL 6 N (2 NORBORNYL)ADENINE; BRADYKININ B2 RECEPTOR; ENALAPRILAT; KININOGEN; NORADRENALIN; BRADYKININ RECEPTOR;

ADRENERGIC NERVE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; DRUG RECEPTOR BINDING; EXOCYTOSIS; GUINEA PIG; HEART INNERVATION; HEART MUSCLE ISCHEMIA; MALE; NERVE ENDING; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; SYMPATHETIC NERVE; ADRENERGIC SYSTEM; ANIMAL; HEART; INNERVATION; NEUROMUSCULAR SYNAPSE; PARACRINE SIGNALING; PHYSIOLOGY;

ANIMALS; AUTOCRINE COMMUNICATION; EXOCYTOSIS; GUINEA PIGS; HEART; MALE; NERVE ENDINGS; NEUROMUSCULAR JUNCTION; NOREPINEPHRINE; PARACRINE COMMUNICATION; RECEPTORS, BRADYKININ; SYMPATHETIC NERVOUS SYSTEM;

EID: 0030611690     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.81.5.774     Document Type: Article

References (77)

1. Parratt JR. Cardioprotection by angiotensin converting enzyme inhibitors: the experimental evidence. Cardiovasc Res. 1994;28:183-189.
2. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
3. Schwieler JH, Hjemdahl P. Influence of angiotensin-converting enzyme inhibition on sympathetic neurotransmission: possible roles of bradykinin and prostaglandins. J Cardiovasc Pharmacol. 1992;20(suppl 9):S39-S46.
4. Rump LC, Bohmann C, Schaible U, Schultze-Seemann W, Schollmeyer PJ. β-Adrenergic, angiotensin II, and bradykinin receptors enhance neurotransmission in human kidney. Hypertension. 1995;26:445-451.
5. 2 receptors. Pflugers Arch. 1996;432(suppl):R99-R106.
6. Minshall RD, Yelamanchi VP, Djokovic A, Miletich DJ, Erdos EG, Rabito SF, Vogel SM. Importance of sympathetic innervation in the positive inotropic effects of bradykinin and ramiprilat. Circ Res. 1994;74:441-447.
7. Chulak C, Couture R, Foucart S. Modulatory effect of bradykinin on the release of noradrenaline from rat isolated atria. Br J Pharmacol. 1995;115:330-334.
8. Vaz-da-Silva M, Magina S, Domingues-Costa A, Moura D, Guimaraes S. The role of the endocardium in the facilitatory effect of bradykinin on electrically-induced release of noradrenaline in rat cardiac ventricle. Br J Pharmacol. 1996;118:364-368.
9. Kübler W, Strasser RH. Signal transduction in myocardial ischaemia. Eur Heart J. 1994;15:437-445.
10. Schömig A, Haass M, Richardt G. Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur Heart J. 1991;12(suppl F):38-47.
11. 3 receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release. J Pharmacol Exp Ther. 1994;271:1259-1266.
12. Kimura E, Hashimoto K, Furukawa S, Hayakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J. 1973;85:635-647.
13. Matsuki T, Shoji T, Yoshida S. Sympathetically induced myocardial ischemia causes the heart to release plasma kinin. Cardiovasc Res. 1987;21:428-432.
14. 9-bradykinin release following reperfusion of the ischaemic rat heart. Br J Pharmacol. 1995;115:476-478.
15. Linz W, Wiemer G, Schölkens BA. Role of kinins in the pathophysiology of myocardial ischemia: in vitro and in vivo studies. Diabetes. 1996;45(suppl 1):S51-S58.
16. Owen PJ, Plevin R, Boarder MR. Characterisation of bradykinin-stimulated release of noradrenaline from cultured bovine adrenal chromaffin cells. J Pharmacol Exp Ther. 1989;248:1231-1236.
17. 3H]noradrenaline from the human neuroblastoma SH-SY5Y. Biochem Pharmacol. 1994;48:23-30.
18. Weiss C, Atlas D. The bradykinin receptor - a putative receptor-operated channel in PCl2 cells: studies of neurotransmitter release and inositol phosphate accumulation. Brain Res. 1991;543:102-110.
19. Seyedi N, Levi R. Bradykinin facilitates norepinephrine exocytosis from cardiac sympathetic nerve endings. FASEB J. 1996;3:A695. Abstract.
20. Aloyo VJ, McIlvain HB, Bhavsar VH, Roberts J. Characterization of norepinephrine accumulation by a crude synaptosomal-mitochondrial fraction isolated from rat heart. Life Sci. 1991;48:1317-1324.
21. 3-receptors in the human heart. Circ Res. 1995;77:206-210.
22. 2-adrenoceptors. Circ Res. 1996;78:475-481.
23. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87:206-210.
24. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 1991;350:350-354.
25. Trendelenburg U. The extraneuronal uptake and metabolism of catecholamines. In: Catecholamines. Berlin, Germany: Springer-Verlag; 1988:279-319.
26. Watson S, Girdlestone D. Receptor and ion channel nomenclature supplement. Trends Pharmacol Sci. 1996:1-81. Abstract.
27. Marley PD, Thomson KA. Inhibition of nicotinic responses of bovine adrenal chromaffin cells by the protein kinase C inhibitor, Ro 31-8220. Br J Pharmacol. 1990;119:416-422.
28. Cambridge D. UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol. 1981;72:413-415.
29. 2 receptor subtype selectivity of adenosine receptor agonists in vivo. J Pharmacol Exp Ther. 1994;268:1166-1173.
30. 1 subtype-selective adenosine receptor antagonist in the guinea pig isolated heart. J Pharmacol Exp Ther. 1992;260:1292-1299.
31. 1MF-2 cells. J Pharmacol Exp Ther. 1995;275:1167-1176.
32. 3-receptor. Eur J Med Chem. 1992;27:511-517.
33. Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W, Schwartz JC. Highly potent and selective ligands for histamine H3-receptors. Nature. 1987;327:117-123.
34. Wirth KJ, Heitsch H, Schölkens BA. Kinin receptor antagonists: unique probes in basic and clinical research. Can J Physiol Pharmacol. 1995;73:797-804.
35. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
36. Plummer TH Jr, Ryan TJ. A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. Biochem Biophys Res Commun. 1981;98:448-454.
37. Yamamoto T. Characterization of guinea-pig high-molecular-weight kininogen as multi-functional molecule. Biochim Biophys Acta. 1987;914:259-274.
38. Margolius HS. Kallikreins and kinins: some unanswered questions about system characteristics and roles in human disease. Hypertension. 1995;26:221-229.
39. Majewski H, Ishac EJN, Musgrave IF. Intraneuronal mechanisms involved in the modulation of noradrenaline release through prejunctional receptors. In: Bevan JA, Majewski H, Maxwell RA, Story DF, eds. Vascular Neuroeffector Mechanisms. Oxford, UK: IRL Press; 1988:243-250.
40. Schroeder GE, Kotsonis P, Musgrave IF, Majewski H. Protein kinasc C involvement in maintenance and modulation of noradrenaline release in the mouse brain cortex. Br J Pharmacol. 1995;116:2757-2763.
41. Kurz T, Richardt G, Seyfarth M, Schömig A. Nonexocytotic noradrenaline release induced by pharmacological agents or anoxia in human cardiac tissue. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:7-16.
42. Brasch H, Sieroslawski L, Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension. 1993;22:699-704.
43. 2-receptor-mediated stimulation of cxocytotic norepinephrine release from cardiac sympathetic neurons. Circulation, 1995;92(suppl I):I-317. Abstract.
44. De Belleroche JS, Bradford HF. Metabolism of beds of mammalian cortical synaptosomes: response to depolarizing influences. J Neurochem. 1972;19:585-602.
45. Opie LH. The Heart: Physiology and Metabolism. 2nd ed. New York, NY: Raven Press Publishers; 1991.
46. Whittaker VP. Thirty years of synaptosome research. J Neurocytol. 1993;22:735-742.
47. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J, Schölkens BA. Hoe 140: a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102:769-773.
48. 2 bradykinin receptor. Proc Natl Acad Sci U S A. 1991;88:7724-7728.
49. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res. 1995;76:773-780.
50. 3H] noradrenaline from SH-SY5Y cells. J Neurochem. 1945;64:1175-1182.
51. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
52. Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, Weitz D, Bohn DL, Wenger HC, Vassil TC, Stone CA. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther. 1981;216:552-557.
53. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Gilman AG, Limbird LE eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Publishing Co; 1996:1707-1792.
54. 1 receptor. Br J Pharmacol. 1993;108:318-322.
55. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983;33:479-494.
56. Werle E, Maier L. Über die chemische und pharmakologische unterscheidung von kallikreinen verschiedener herkunft. Biochem Z. 1952;323:279-283.
57. Zeitlin IJ, Fagbemi SO, Parratt JR. Enzymes in normally perfused and ischaemic dog hearts which release a substance with kinin like activity. Cardiovasc Res. 1989;23:91-97.
58. Nolly HL, Saed G, Scicli G, Carretero OA, Scicli AG. The kallikrein-kinin system in cardiac tissue. Agents Actions Suppl. 1992;38:62-72.
59. Schmaier AH, Zuckerberg A, Silverman C, Kuchibhotla J, Tuszynski GP, Colman RW. High-molecular weight kininogen: a secreted platelet protein. J Clin Invest. 1983;71:1477-1489.
60. Chao J, Chao L, Ando T, Margolius H. Kallikrein, kallikrein binding protein and kininogen in rat brain and in neuroblastoma×glioma hybrid cells. Clin Res. 1985;33:532A. Abstract.
61. Vogel R. Kallikrein-inhibitors. In: Erdös EG, ed. Handbook of Experimental Pharmacology: Bradykinin, Kallidin and Kallikrein. Berlin/Heidelberg, Germany/New York, NY: Springer-Verlag; 1979;25(suppl):163-225.
62. Corthorn J, Roblero J. Release of activatable kallikrein by isolated rat kidneys. Hypertension. 1981;3(suppl II):II-41. Abstract.
63. EI-Dahr SS, Yosipiv I. Developmentally regulated kallikrein enzymatic activity and gene transcription rate in maturing rat kidneys. Am J Physiol. 1993;265:F146-F150.
64. Oza NB, Schwartz JH, Goud HD, Levinsky NG. Rat aortic smooth muscle cells in culture express kallikrein, kininogen, and bradykininase activity. J Clin Invest. 1990;85:597-600.
65. Shori DK, Proctor GB, Chao J, Chan KM, Garrett JR. New specific assays for tonin and tissue kallikrein activities in rat submandibular glands: assays reveal differences in the effects of sympathetic and parasympathetic stimulation on proteinases in saliva. Biochem Pharmacol. 1992;43:1209-1217.
66. Hecker M, Pörsti I, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol. 1994;111:238-244.
67. 2 receptor. Immunopharmacology. 1996;33:93-94.
68. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am J Physiol Endocrinol Metab. 1993;264:E631-E637.
69. Schömig A. Catecholamines in myocardial ischemia: systemic and cardiac release. Circulation. 1990;82:13-22.
70. Pinto YM, Buikema H, Van Gilsi WH. Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses. Clin Exp Hypertens. 1995;17:441-468.
71. Malik KU, Nasjletti A. Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries. Circ Res. 1976;38:26-30.
72. Carlsson L, Abrahamsson T. Ramiprilat attenuates the local release of noradrenaline in the ischemic myocardium. Eur J Pharmacol. 1989;166:157-164.
73. Scicli AG. Increases in cardiac kinins as a new mechanism to protect the heart. Hypertension. 1994;23:419-421.
74. Rubin LE, Levi R. Protective role of bradykinin in cardiac anaphylaxis: coronary-vasodilating and antiarrhythmic activities mediated by autocrine/paracrine mechanisms. Circ Res. 1995;76:434-440.
75. Schölkens BA. Kinins in the cardiovascular system. Immunopharmacology. 1996;33:209-216.
76. Busse R, Hecker M, Fleming I. Control of nitric oxide and prostacyclin synthesis in endothelial cells. Arzneimittelforschung. 1994;44:392-396.
77. Tschöpe C, Gavriluk V, Reinecke A, Seidl U, Riester U, Hilgenfeldt U, Ritz E, Unger T. Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology. 1996;33:344-348.